• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Cryopreserved Platelets are Hemostatically Functional in Vitro

March 23, 2016

Activated platelet, SEMInventory and storage of cryopreserved platelets (CPP) would be simple in comparison to platelets that are normally stored at room temperature for up to 7 days. Previous in vivo studies have suggested that CPPs are safe and hemostatically effective. However, in vitro studies have provided discrepant results. In order to investigate the in vitro properties of CPP, fresh whole blood was collected from 8 donors. In this 4-arm study, hemostatic properties of whole blood were compared to platelet-depleted whole blood, and whole blood with restored platelets (cryopreserved or stored in standard liquid for 5 days). Results suggest that CPP-restored whole blood has the fastest clotting time, can form stable platelet clots, and can effectively support the conversion of prothrombin to thrombin and fibrin without a risk of thrombosis. Further research into the safety of CPP in vivo is necessary as CPPs may be helpful in some clinical settings.

Reference

1. Cid J, Escolar G, Galan A, Lopez-Vilchez I, Molina P, Diaz-Ricart M, Lozano M, Dumont LJ. In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets. Transfusion 2016;56: 580-6.

Filed Under

  • CME
  • News
  • Platelet Transfusion

Recommended

  • Red Cell Exchange for Patients with Sickle Cell Disease: an AABB Report

  • Donor Interventions Increase Donor’s Return for Future Donations

  • RBC Transfusions Reduce Fatigability in Hospitalized Patients with Anemia

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Interventions to Prevent Vasovagal Reactions among Blood Donors

  • Nipocalimab for Severe Hemolytic Disease of the Fetus and Newborn

  • Clinical Guidelines for Anemia and Chronic Kidney Disease

  • Ferritin-Guided Donation Policies Decrease Iron Deficiency

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley